Your browser doesn't support javascript.
loading
The Prevalence and Management of Saliva Problems in Motor Neuron Disease: A 4-Year Analysis of the Scottish Motor Neuron Disease Register.
Pearson, Iona; Glasmacher, Stella A; Newton, Judith; Beswick, Emily; Mehta, Arpan R; Davenport, Richard; Chandran, Siddharthan; Pal, Suvankar.
Afiliação
  • Pearson I; College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, United Kingdom.
  • Glasmacher SA; Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.
  • Newton J; Anne Rowling Regenerative Neurology Clinic, Royal Infirmary, Edinburgh, United Kingdom.
  • Beswick E; Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.
  • Mehta AR; Anne Rowling Regenerative Neurology Clinic, Royal Infirmary, Edinburgh, United Kingdom.
  • Davenport R; Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, United Kingdom.
  • Chandran S; Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.
  • Pal S; Anne Rowling Regenerative Neurology Clinic, Royal Infirmary, Edinburgh, United Kingdom.
Neurodegener Dis ; 20(4): 147-152, 2020.
Article em En | MEDLINE | ID: mdl-33902047
INTRODUCTION: Saliva problems are common and distressing for people with motor neuron disease (pwMND). Despite clinical guidelines for assessment and treatment, management of saliva problems has received little research attention. OBJECTIVE: We aimed to investigate the prevalence of saliva problems in pwMND, their association with clinical factors, and their management practice using a highly curated population-based register for motor neuron disease (MND) with 99% case ascertainment. METHODS: We conducted an analysis of pwMND diagnosed between January 2015 and October 2019 using the Scottish MND Register (CARE-MND [Clinical, Audit, Research, and Evaluation of MND]). The association between clinical factors and saliva problems was investigated using univariate and multivariable logistic regression; results are reported as odds ratio (OR) and 95% confidence intervals. A survey of health-care professionals involved in the care of pwMND was performed to contextualize the findings. RESULTS: 939 pwMND were included. Prevalence of saliva problems was 31.3% (294). Bulbar onset (OR 9.46 [4.7, 19.2]; p < 0.001) but not age, sex, time to diagnosis, or MND subtype were independently associated with the presence of saliva problems in multivariable regression, and 52.7% (155) of those with saliva problems received pharmacological management. The most commonly used medications were hyoscine, amitriptyline, carbocisteine, glycopyrrolate, and atropine. Evidence base (8, 72.7%) and local guidelines (10, 90.9%) were cited as the most important factors influencing treatment decision by survey respondents (n = 11). CONCLUSION: Saliva problems are common and associated with bulbar onset MND. A substantial proportion of pwMND with saliva problems did not receive recommended treatments. Future research is required to determine the relative efficacy of individual pharmacological treatments.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença dos Neurônios Motores / Esclerose Lateral Amiotrófica Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença dos Neurônios Motores / Esclerose Lateral Amiotrófica Idioma: En Ano de publicação: 2020 Tipo de documento: Article